CD8A and neoplasm: In a study by Berghuis et al. (2011), a follow-up over 100 months demonstrated that patients with high CD8+tumor-infiltrating lymphocyte (TIL) expression had an overall survival rate of 90 %, compared to those with low CD8+TIL expression.